Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer (Therapy)
Combination Therapy Demonstrates Significant Activity
November 13th, 1995
A combination therapy of the new anticancer agent, Taxotere (docetaxel), and Adriamycin (doxorubicin) demonstrated significant activity and a well tolerated safety profile in the first line treatment of metastatic (advanced) breast cancer. Results from a Phase I study, were presented at the 8th Annual European Cancer Conference (ECCO-8) in Paris, France. In the study, conducted at the Institut Curie, in Paris, and Hopital Paul-Brousse in Villejuif, France, patients with metastatic breast cancer (cancer that has spread to other sites in the body) were treated with both Taxotere and doxorubicin. Metastatic breast cancer is difficult to treat with...
Source: Women's Health Weekly (1995-11-13)
|
